Tag: Cybin Corp - Page 5 - Psychedelic Alpha

Read more about the article Cybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug Applications

Cybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug Applications

Post published:April 13, 2021
Post category:Press Release

Read more about the article Cybin Announces Senior Management Changes to Lead Buildout of Development and Clinical Capabilities in the United States and Europe

Cybin Announces Senior Management Changes to Lead Buildout of Development and Clinical Capabilities in the United States and Europe

Post published:March 30, 2021
Post category:Press Release

Read more about the article Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)

Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)

Post published:March 22, 2021
Post category:Press Release

Read more about the article Cybin Progresses Two Psychedelic Investigational New Drug (“IND”) Candidates and Announces Completion of Its 20th Pre-Clinical Study

Cybin Progresses Two Psychedelic Investigational New Drug (“IND”) Candidates and Announces Completion of Its 20th Pre-Clinical Study

Post published:March 17, 2021
Post category:Press Release

Read more about the article Cybin Announces API Synthesis and Optimization of Multiple Tryptamine Derivatives and Nomination of Two Deuterated Candidates for Full IND Enabling Studies Based on Second Milestone Achievement Pursuant to the Adelia Acquisition

Cybin Announces API Synthesis and Optimization of Multiple Tryptamine Derivatives and Nomination of Two Deuterated Candidates for Full IND Enabling Studies Based on Second Milestone Achievement Pursuant to the Adelia Acquisition

Post published:March 9, 2021
Post category:Press Release

Read more about the article Cybin Inc. Shares Commence Trading on the OTCQB Venture Market on March 8, 2021

Cybin Inc. Shares Commence Trading on the OTCQB Venture Market on March 8, 2021

Post published:March 8, 2021
Post category:Press Release

Read more about the article Cybin Inc. Announces Uplisting to OTCQB Venture Market

Cybin Inc. Announces Uplisting to OTCQB Venture Market

Post published:March 3, 2021
Post category:Press Release

Read more about the article Cybin Announces Closing of Upsized Bought Deal Offering

Cybin Announces Closing of Upsized Bought Deal Offering

Post published:February 4, 2021
Post category:Press Release

Read more about the article Cybin Announces CDN$20 Million Bought Deal Offering

Cybin Announces CDN$20 Million Bought Deal Offering

Post published:January 18, 2021
Post category:Press Release

Read more about the article Cybin Announces API Synthesis of Multiple Tryptamine Derivatives Based on the First Milestone Achievement Pursuant to the Adelia Acquisition

Cybin Announces API Synthesis of Multiple Tryptamine Derivatives Based on the First Milestone Achievement Pursuant to the Adelia Acquisition

Post published:January 11, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.